Home › Compare › BRIBF vs NNN

BRIBF vs NNN: Dividend Comparison 2026

BRIBF yields 1062.70% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRIBF wins by $32084463.97M in total portfolio value
10 years
BRIBF
BRIBF
● Live price
1062.70%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32084464.00M
Annual income
$27,073,008,093,454.87
Full BRIBF calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — BRIBF vs NNN

📍 BRIBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRIBFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRIBF + NNN cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BRIBF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRIBF
Annual income on $10K today (after 15% tax)
$90,329.44/yr
After 10yr DRIP, annual income (after tax)
$23,012,056,879,436.64/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, BRIBF beats the other by $23,012,056,877,194.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRIBF + NNN for your $10,000?

BRIBF: 50%NNN: 50%
100% NNN50/50100% BRIBF
Portfolio after 10yr
$16042232.01M
Annual income
$13,536,504,048,046.14/yr
Blended yield
84.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

BRIBF
No analyst data
Altman Z
19.2
Piotroski
2/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRIBF buys
0
NNN buys
0
No recent congressional trades found for BRIBF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRIBFNNN
Forward yield1062.70% ✓5.68%
Annual dividend / share$2.00$2.38 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6% ✓
Portfolio after 10y$32084464.00M ✓$25.6K
Annual income after 10y$27,073,008,093,454.87 ✓$2,637.42
Total dividends collected$31704729.30M ✓$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BRIBF vs NNN ($10,000, DRIP)

YearBRIBF PortfolioBRIBF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$116,970$106,269.93$10,737$617.02+$106.2K → BRIBF
2$1,286,876$1,161,718.25$11,577$710.93+$1.28M → BRIBF
3$13,321,776$11,944,818.28$12,538$822.59+$13.31M → BRIBF
4$129,817,926$115,563,625.92$13,645$956.06+$129.80M → BRIBF
5$1,191,375,681$1,052,470,500.56$14,925$1,116.51+$1191.36M → BRIBF
6$10,301,704,979$9,026,933,000.21$16,415$1,310.57+$10301.69M → BRIBF
7$83,971,400,363$72,948,576,035.34$18,158$1,546.77+$83971.38M → BRIBF
8$645,568,504,677$555,719,106,288.88$20,213$1,836.20+$645568.48M → BRIBF
9$4,683,603,649,023$3,992,845,349,018.69$22,649$2,193.37+$4683603.63M → BRIBF
10$32,084,463,997,910$27,073,008,093,454.87$25,558$2,637.42+$32084463.97M → BRIBF

BRIBF vs NNN: Complete Analysis 2026

BRIBF — Stock

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Full BRIBF Calculator →

NNN — REIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this BRIBF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRIBF vs SCHDBRIBF vs JEPIBRIBF vs OBRIBF vs KOBRIBF vs MAINBRIBF vs ADCBRIBF vs EPRTBRIBF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.